Three companies led by Indian American entrepreneurs—Qure.ai, CRISPR Therapeutics, and Vertex Pharmaceuticals—have secured their spots on the 2025 TIME100 Most Influential Companies list. This annual accolade by TIME magazine recognizes companies worldwide that are shaping the future with their impact, innovation, and leadership.
The prominence of these three firms highlights the growing influence of Indian Americans in the fields of healthcare technology and biotechnology, as well as their commitment to driving solutions that extend far beyond business success.
Recognizing innovation and impact
The selection of these companies reflects TIME magazine’s criteria for influence, which assesses the ambition, innovation, measurable successes, and global impact of companies across various fields. In 2025, TIME also launched its Impact Awards, an offshoot that gives further distinction to companies making significant contributions in specific domains such as health, artificial intelligence, sustainability, equality, and culture.
Vertex Pharmaceuticals, under the leadership of Dr. Reshma Kewalramani, was one of just five companies to receive an inaugural Impact Award for its contributions to health, a testament to the company’s pioneering work in drug development and transformative patient care.
The story of Qure.ai
Qure.ai stands at the forefront of healthcare technology by leveraging artificial intelligence to revolutionize diagnostic imaging. Led by Prashant Warier, Qure.ai develops deep-learning algorithms capable of interpreting medical images like X-rays, ultrasounds, and CT scans. In an age where healthcare systems globally are strained by growing and aging populations, Qure.ai’s technology becomes crucial, especially in regions where access to specialists is limited.
By providing rapid, accurate insights that rival those of human radiologists, Qure.ai enables early detection of conditions such as lung cancer, brain trauma, and tuberculosis. The technology is now in use in over 100 countries and holds 18 FDA clearances in the U.S., including significant milestones in AI for lung cancer diagnosis.
For Warier, Qure.ai’s tools serve as a highly trained assistant—one that never tires and can extend the reach of quality healthcare to underserved communities worldwide.
Transformative gene editing at CRISPR therapeutics
CRISPR Therapeutics’s impact stems from its cutting-edge work in gene editing, a technology poised to reshape treatment options for both rare and common diseases. Helmed by Sam Kulkarni, the company achieved a landmark in 2024 with U.S. FDA approval for gene therapy cures targeting sickle cell disease and beta thalassemia.
It’s an honor to see CRISPR Therapeutics named on the TIME100 Most Influential Companies of 2025 list!
It’s an honor to see CRISPR Therapeutics named on the TIME100 Most Influential Companies of 2025 list! www.linkedin.com
It’s an honor to see CRISPR Therapeutics named on the TIME100 Most Influential Companies of 2025 list! Thank you TIME for the recognition and congratulations to all #TIME100Companies for their impact across the globe. | 42 comments on LinkedIn
Rather than limiting its ambitions to rare disorders, CRISPR Therapeutics is expanding trials to tackle widespread health concerns, such as high cholesterol and autoimmune conditions like lupus. Kulkarni emphasizes making gene editing more accessible and affordable, aiming to bring these next-generation therapies to millions in the near future.
By lowering barriers to novel treatments, CRISPR Therapeutics is positioned to transform healthcare for a broad segment of the global population in the coming decade.
Vertex Pharmaceuticals and rational drug design
Vertex Pharmaceuticals, with Dr. Reshma Kewalramani at the helm, carries a strong legacy of scientific innovation and impactful drug development. The company, jointly with CRISPR Therapeutics, brought to market Casgevy, the first CRISPR-based medicine approved by the FDA for treating sickle cell disease and beta thalassemia.
Vertex also broke new ground in 2025 by launching Journavx, the first FDA-approved non-opioid painkiller in more than 20 years, alongside securing approval for its fifth cystic fibrosis therapy. Kewalramani’s leadership is defined by a philosophy of rational drug design: intentionally creating treatments that directly target known disease mechanisms, rather than relying on trial and error.
TIME's list of the 100 Most Influential Companies of 2025 is out now, and we are proud to be a part of it — and for Vertex Pharmaceuticals to be recognized with an inaugural Impact Award in Health. | Reshma Kewalramani, MD FASN
TIME's list of the 100 Most Influential Companies of 2025 is out now, and we are proud to be a part of it — and for Vertex Pharmaceuticals to be recognized with an inaugural Impact Award in Health. | Reshma Kewalramani, MD FASN www.linkedin.com
TIME's list of the 100 Most Influential Companies of 2025 is out now, and we are proud to be a part of it — and for Vertex Pharmaceuticals to be recognized with an inaugural Impact Award in Health. These recognitions reflect the impact of our science, the strength of our strategy, and the people behind it. Congratulations to Vertexians around the globe! #TIME100Companies | 138 comments on LinkedIn
Current efforts focus on advanced therapies for type 1 diabetes—as the company tests a cell-based approach that could free some patients from insulin injections—and on chronic kidney disease, following the acquisition of Alpine Immune Sciences to expand their research portfolio. Kewalramani insists on avoiding “me-too medicines,” pushing instead for curative breakthroughs that meaningfully change lives.
Broader recognition and lasting influence
These recognitions for Qure.ai, CRISPR Therapeutics, and Vertex Pharmaceuticals sit alongside other industry leaders awarded in 2025 across technology, sustainability, equality, and culture. The achievements of Indian American-led companies affirm not only a legacy of professional excellence but also the potential to set new standards in patient care and research.
Their inclusion in the TIME100 Most Influential Companies list exemplifies the transformative contributions of Indian American entrepreneurs to global health innovation. Through vision, expertise, and relentless pursuit of breakthrough solutions, these leaders and their companies are shaping a healthier, more promising future for millions around the world.
